Cargando…

CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?

BACKGROUND: Inhibitors of the epidermal growth factor (EGFR) represent an effective therapeutic option for patients with metastatic colorectal carcinoma, free of activating mutations in KRAS and NRAS. However, the research of mutations is of high cost and scarcely accessible. The expression of the E...

Descripción completa

Detalles Bibliográficos
Autores principales: PINTO, Thiago David Alves, ALVES, Thaís David das Neves, PINTO, Sebastião Alves, OLIVEIRA, Enio Chaves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Colégio Brasileiro de Cirurgia Digestiva 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195465/
https://www.ncbi.nlm.nih.gov/pubmed/34133521
http://dx.doi.org/10.1590/0102-672020210001e1574
_version_ 1783706507583422464
author PINTO, Thiago David Alves
ALVES, Thaís David das Neves
PINTO, Sebastião Alves
OLIVEIRA, Enio Chaves
author_facet PINTO, Thiago David Alves
ALVES, Thaís David das Neves
PINTO, Sebastião Alves
OLIVEIRA, Enio Chaves
author_sort PINTO, Thiago David Alves
collection PubMed
description BACKGROUND: Inhibitors of the epidermal growth factor (EGFR) represent an effective therapeutic option for patients with metastatic colorectal carcinoma, free of activating mutations in KRAS and NRAS. However, the research of mutations is of high cost and scarcely accessible. The expression of the EGFR by immunohistochemistry predicting the mutation status of the expanded RAS (KRAS and NRAS), may allow treatment by a diagnostic method less costly and more accessible. AIM: Investigate the correlation between the clinical-pathological data, the cytoplasmic-membrane expression of the EGFR and the mutational status of the expanded RAS. METHOD: A total of 139 patients with colorectal carcinoma from the archives of Instituto Goiano de Oncologia e Hematologia were evaluated. RESULTS: Mutation of the expanded RAS was detected in 78 (56.1%) cases. The EGFR expression was stratified in 23 (16.5%) “positive”, 49 (35.2%) "negative" and 67 (48.2%) "uncertain". No significant correlation was found between the mutational status of the RAS and the EGFR expression in comparison to age, gender, location, histological type, histological grade and stage. From 23 "positive” cases, 21 (91.3%) showed wild-type RAS gene, and 49 "negative”, 41 (83.7%) presented mutation, resulting in a strong association between EGFR "positive", "negative” groups and the mutational status of the RAS (p<0.001), with 86.1% of accuracy. CONCLUSIONS: The cytoplasmic-membrane analysis of the EGFR expression stratified into "positive", "negative" and "uncertain" predicts mutational status of the RAS in 51.7% of the cases (p<0.001), with 86.1% of accuracy.
format Online
Article
Text
id pubmed-8195465
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Colégio Brasileiro de Cirurgia Digestiva
record_format MEDLINE/PubMed
spelling pubmed-81954652021-06-24 CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS? PINTO, Thiago David Alves ALVES, Thaís David das Neves PINTO, Sebastião Alves OLIVEIRA, Enio Chaves Arq Bras Cir Dig Original Article BACKGROUND: Inhibitors of the epidermal growth factor (EGFR) represent an effective therapeutic option for patients with metastatic colorectal carcinoma, free of activating mutations in KRAS and NRAS. However, the research of mutations is of high cost and scarcely accessible. The expression of the EGFR by immunohistochemistry predicting the mutation status of the expanded RAS (KRAS and NRAS), may allow treatment by a diagnostic method less costly and more accessible. AIM: Investigate the correlation between the clinical-pathological data, the cytoplasmic-membrane expression of the EGFR and the mutational status of the expanded RAS. METHOD: A total of 139 patients with colorectal carcinoma from the archives of Instituto Goiano de Oncologia e Hematologia were evaluated. RESULTS: Mutation of the expanded RAS was detected in 78 (56.1%) cases. The EGFR expression was stratified in 23 (16.5%) “positive”, 49 (35.2%) "negative" and 67 (48.2%) "uncertain". No significant correlation was found between the mutational status of the RAS and the EGFR expression in comparison to age, gender, location, histological type, histological grade and stage. From 23 "positive” cases, 21 (91.3%) showed wild-type RAS gene, and 49 "negative”, 41 (83.7%) presented mutation, resulting in a strong association between EGFR "positive", "negative” groups and the mutational status of the RAS (p<0.001), with 86.1% of accuracy. CONCLUSIONS: The cytoplasmic-membrane analysis of the EGFR expression stratified into "positive", "negative" and "uncertain" predicts mutational status of the RAS in 51.7% of the cases (p<0.001), with 86.1% of accuracy. Colégio Brasileiro de Cirurgia Digestiva 2021-06-11 /pmc/articles/PMC8195465/ /pubmed/34133521 http://dx.doi.org/10.1590/0102-672020210001e1574 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Original Article
PINTO, Thiago David Alves
ALVES, Thaís David das Neves
PINTO, Sebastião Alves
OLIVEIRA, Enio Chaves
CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?
title CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?
title_full CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?
title_fullStr CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?
title_full_unstemmed CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?
title_short CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?
title_sort cytoplasmic-membrane egfr predicts expanded ras mutation status in colorectal carcinomas?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195465/
https://www.ncbi.nlm.nih.gov/pubmed/34133521
http://dx.doi.org/10.1590/0102-672020210001e1574
work_keys_str_mv AT pintothiagodavidalves cytoplasmicmembraneegfrpredictsexpandedrasmutationstatusincolorectalcarcinomas
AT alvesthaisdaviddasneves cytoplasmicmembraneegfrpredictsexpandedrasmutationstatusincolorectalcarcinomas
AT pintosebastiaoalves cytoplasmicmembraneegfrpredictsexpandedrasmutationstatusincolorectalcarcinomas
AT oliveiraeniochaves cytoplasmicmembraneegfrpredictsexpandedrasmutationstatusincolorectalcarcinomas